Biotech News
Related news
MXCTMaxCyte2026-08-12 20:05 EST
MaxCyte Reports Second Quarter 2026 Financial Results
MXCTMaxCyte2026-07-15 20:05 EST
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
PHARPharming Group2026-07-30 05:00 EST
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
OCGNOcugen2026-10-22 11:00 EST
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
SRPTSarepta Therapeutics2026-10-22 12:30 EST
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
TSHATaysha Gene Therapies2026-08-04 20:00 EST
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
CRSPCRISPR Therapeutics2026-08-03 20:15 EST
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
NTLAIntellia2026-07-30 12:00 EST
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
OCGNOcugen2026-07-28 20:01 EST
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
ABEOAbeona Therapeutics2026-08-06 11:30 EST
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
MaxCyte
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...
Recent company news
MXCTMaxCyte2026-10-14 12:05 EST
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MXCTMaxCyte2026-09-23 12:05 EST
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MXCTMaxCyte2026-09-11 20:30 EST
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MXCTMaxCyte2026-08-19 12:05 EST
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MXCTMaxCyte2026-08-12 20:05 EST
MaxCyte Reports Second Quarter 2026 Financial Results
Stock data
- Close
- 1.47 USD
- Market cap
- 131.76M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States